Capricor’s stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year. The medical sector company plans to file the ...

Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its ...

Edward Tenthoff’s rating is based on Capricor Therapeutics’ promising development of deramiocel, a treatment for cardiomyopathy in Duchenne Muscular Dystrophy (DMD) patients. The Phase II HOPE ...

Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a ...

We expect deramiocel to be a lifelong treatment, with an infusion delivered quarterly,” added Marbán. The HOPE-2 OLE study (NCT03406780) enrolled 13 patients with DMD cardiomyopathy.

Capricor shares have been on the rise since late last week, when the company reported positive long-term study data for its lead asset, deramiocel, in Duchenne muscular dystrophy. The stock ...

Capricor Therapeutics shares rose in premarket trading Tuesday after the company said it plans to file a biologics license application for Deramiocel, its Duchenne muscular dystrophy ...

Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S.

The reaffirmation follows a recent presentation at the World Muscle Society congress, highlighting the potential of Capricor's deramiocel in treating Duchenne muscular dystrophy (DMD). The ...

Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...